演題抄録

若手臨床腫瘍医のための技術ワークショップ

開催概要
開催回
第51回・2013年・京都
 

Tumor genotyping for stratified therapy trials and translational research

演題番号 : TW2-4

[筆頭演者]
Leif W. Ellisen:1 
[共同演者]
Darrel Borger:1、A. John Iafrate:2、Dora Dias Santa-Gata:2

1:Massachusetts General Hospital Cancer Center, USA、2:MGH Pathology Department, USA

 

Patient stratification by tumor genetic profile is emerging as an important component of early-phase clinical trial design. We developed and validated a multiplex tumor mutation detection platform in a CLIA environment, which was offered as a physician-ordered test at a major US cancer center. Testing more than 5,000 patients to date has allowed design of novel, genotype-directed clinical trials and has provided new insights into treatment response, de novo and acquired drug resistance. Ongoing expansion of clinical tumor genetic analysis using next generation sequencing presents near-term technical and interpretive challenges, but this approach will be essential for accelerating progress towards individualized cancer therapy.

前へ戻る